Rytary Capsule, Extended Release
Product Images NDC 64896-664

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rytary (NDC 64896-664). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure 1 (Rytary Extended Release Capsules 1)

Chemical structure diagram of Carbidopa monohydrate, showing the molecular arrangement including a benzene ring with hydroxyl groups and hydrazine side chain.*

FDA Label Image

Chemical Structure 2 (Rytary Extended Release Capsules 2)

Chemical structure diagram of Carbidopa and Levodopa showing a benzene ring with hydroxyl groups and an attached amino acid side chain. This structure represents the active ingredients in RYTARY extended-release capsules by Amneal Pharmaceuticals LLC.*

FDA Label Image

1 (Rytary Extended Release Capsules 3)

Label for RYTARY extended-release capsules containing 23.75 mg carbidopa and 95 mg levodopa per capsule. The label shows dosage information, manufacturer Bora Pharmaceutical Laboratories Inc., distributor Amneal Pharmaceuticals LLC, and a package size of 100 capsules. It includes storage instructions and a barcode, with a purple and orange color scheme.*

FDA Label Image

1 (Rytary Extended Release Capsules 4)

RYTARY 36.25 mg / 145 mg extended-release capsules packaging label. The label shows the drug's generic ingredients, carbidopa and levodopa, and the strength of each capsule. It indicates bottle quantity of 100 capsules and has storage instructions, manufacturer information (Bora Pharmaceutical Laboratories Inc., Taiwan), and distributor details (Amneal Pharmaceuticals LLC). The label includes a barcode and space for lot and expiration date.*

FDA Label Image

1 (Rytary Extended Release Capsules 5)

RYTARY extended-release capsules containing 48.75 mg carbidopa and 195 mg levodopa. The label shows dosage information, storage instructions, and manufacturer details, including Bora Pharmaceutical Laboratories Inc. in Taiwan and Amneal Pharmaceuticals LLC as distributor. The package contains 100 capsules.*

FDA Label Image

1 (Rytary Extended Release Capsules 6)

Label for RYTARY extended-release capsules containing carbidopa 61.25 mg and levodopa 245 mg. The label includes the product name, strengths, dosage form, quantity of 100 capsules, storage instructions, manufacturer Bora Pharmaceutical Laboratories Inc., and distributor Amneal Pharmaceuticals LLC. The label also features the barcode and a lot and expiration date area.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.